Why the study?
Does the addition of glycoprotein IIb/IIIa receptor inhibitor or substitution of low-molecular-weight heparin improve outcomes in prior aspirin users presenting with acute coronary syndromes?
Does the addition of glycoprotein IIb/IIIa receptor inhibitor or substitution of low-molecular-weight heparin improve outcomes in prior aspirin users presenting with acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
Prior aspirin use in acute coronary syndrome patients identifies a high-risk cohort that benefits from more aggressive antithrombotic therapy, such as glycoprotein IIb/IIIa inhibitors or low-molecular-weight heparin.
The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome. The etiology of this increased risk awaits clarification, but prior aspirin use may be associated with altered thrombus composition which is more resistant to current treatment modalities as compared to thrombus formation in subjects without prior aspirin use. Post hoc analysis of acute coronary syndrome trials has shown that prior aspirin users treated with unfractionated heparin are at particularly high risk. The addition of glycoprotein IIb/IIIa receptor inhibitor to unfractionated heparin or substitution of low-molecular-weight heparin significantly improves outcomes in prior aspirin users. The prognostic significance of prior aspirin use in acute coronary syndromes has important implications not only in clinical practice, but also in the design and interpretation of clinical trials.
No takes yet. Share an insight, caveat, or question.
Lancaster et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: